Document is current

Article History

Received: 29 June 2019

Revised: 11 December 2019

Accepted: 3 January 2020

First Online: 9 March 2020

Conflict of interest

: M.A.D. has received consulting fees and honoraria from Amgen, Bristol-Myers Squibb (BMS), Takeda, Celgene, and Janssen. R.N. has received consulting fees and research funding from Takeda, Celgene, BMS, Amgen, and Janssen. K.W. has received honoraria from Amgen, BMS, Celgene, Janssen, Novartis, and Takeda; consulting fees from Amgen, Adaptive, BMS, Celgene, Janssen, Takeda, Sanofi, and Juno; and research funding from Amgen, Celgene, Sanofi, and Janssen. D.S.S. has received consulting fees from Takeda, Karyopharm, Merck, Celgene, Janssen, BMS, and Amgen; honoraria from Takeda, Karyopharm, Merck, Celgene, Janssen, BMS, Novartis, and Amgen; served on speakers’ bureaus for Takeda, Merck, Celgene, Janssen, BMS, Novartis, and Amgen; and has received research funding from Celgene. R.H. has received consulting fees, honoraria, and research funding from Amgen, Takeda, Celgene, Janssen, AbbVie, Novartis, PharmaMar, and BMS. M.-V.M. has received consulting fees from and served on Board of Directors/advisory committees for AbbVie, Amgen, GlaxoSmithKline, Takeda, Janssen, and Celgene and honoraria from Amgen, Takeda, Janssen, and Celgene. M.C. has received honoraria from and served on Board of Directors/advisory committees for AbbVie, BMS, Takeda, GlaxoSmithKline, Adaptive Biotechnologies, Janssen, Celgene, and Amgen and served on speakers’ bureaus for and received research funding from Janssen and Celgene. M.H. and A.Z.-K. are employees of, and own stock in, Amgen. P.M. has received honoraria from, and served on Board of Directors/advisory committees for, Amgen, Celgene, Janssen, Takeda, and AbbVie and served on speakers’ bureaus for Amgen, Celgene, Janssen, and AbbVie.